As of 2024-07-27, the EV/EBITDA ratio of Intra-Cellular Therapies Inc (ITCI) is -63.51. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. ITCI's latest enterprise value is 8,346.95 mil USD. ITCI's TTM EBITDA according to its financial statements is -131.42 mil USD. Dividing these 2 quantities gives us the above ITCI EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 10.6x - 17.1x | 13.3x |
| Forward P/E multiples | 17.2x - 21.3x | 20.4x |
| Fair Price | (20.09) - (19.91) | (19.62) |
| Upside | -125.0% - -124.8% | -124.4% |
| Date | EV/EBITDA |
| 2024-07-26 | -63.51 |
| 2024-07-25 | -63.88 |
| 2024-07-24 | -61.01 |
| 2024-07-23 | -61.75 |
| 2024-07-22 | -60.37 |
| 2024-07-19 | -59.07 |
| 2024-07-18 | -59.14 |
| 2024-07-17 | -60.40 |
| 2024-07-16 | -62.05 |
| 2024-07-15 | -62.15 |
| 2024-07-12 | -61.70 |
| 2024-07-11 | -61.85 |
| 2024-07-10 | -61.02 |
| 2024-07-09 | -58.44 |
| 2024-07-08 | -56.42 |
| 2024-07-05 | -54.81 |
| 2024-07-03 | -54.42 |
| 2024-07-02 | -53.99 |
| 2024-07-01 | -53.55 |
| 2024-06-28 | -53.95 |
| 2024-06-27 | -55.95 |
| 2024-06-26 | -56.04 |
| 2024-06-25 | -57.11 |
| 2024-06-24 | -59.64 |
| 2024-06-21 | -60.45 |
| 2024-06-20 | -59.63 |
| 2024-06-18 | -59.57 |
| 2024-06-17 | -54.26 |
| 2024-06-14 | -53.38 |
| 2024-06-13 | -53.89 |
| 2024-06-12 | -53.72 |
| 2024-06-11 | -54.47 |
| 2024-06-10 | -54.42 |
| 2024-06-07 | -53.89 |
| 2024-06-06 | -54.00 |
| 2024-06-05 | -53.41 |
| 2024-06-04 | -53.46 |
| 2024-06-03 | -53.89 |
| 2024-05-31 | -52.95 |
| 2024-05-30 | -51.67 |
| 2024-05-29 | -52.39 |
| 2024-05-28 | -51.65 |
| 2024-05-24 | -51.58 |
| 2024-05-23 | -52.25 |
| 2024-05-22 | -53.00 |
| 2024-05-21 | -52.76 |
| 2024-05-20 | -51.41 |
| 2024-05-17 | -51.15 |
| 2024-05-16 | -52.38 |
| 2024-05-15 | -52.63 |